Abstract: Ecteinascidin formulations, methods of preparing the same, articles of manufacture and kits with such formulations, and methods of treating proliferative diseases with the same formulations are provided.
Type:
Grant
Filed:
October 9, 2014
Date of Patent:
June 18, 2019
Assignee:
PHARMA MAR, S.A., SOCIEDAD UNIPERSONAL
Inventors:
Jacob Hendrik Beijnen, Bastiaan Nuijen, Pilar Calvo Salve, Maria Tobio Barreira
Abstract: Ecteinascidin formulations, methods of preparing the same, articles of manufacture and kits with such formulations, and methods of treating proliferative diseases with the same formulations are provided.
Type:
Grant
Filed:
October 28, 2005
Date of Patent:
November 25, 2014
Assignee:
Pharma Mar, S.A., Sociedad Unipersonal
Inventors:
Jacob Hendrik Beijnen, Bastiaan Nuijen, Pilar Calvo Salve, Maria Tobio Barreira
Abstract: A method for improving the cytotoxic effect of Ecteinascidin-743 (ET-743) or an analog thereof on a tumor cell population in a patient the method including administering to the patient, sequentially or simultaneously, a therapeutically effective combination of a composition including ET-743 and an amount of a composition including a PARP-1 inhibitor effective to increase the cytotoxic effect of ET-743 on the tumor cell population. Anti-tumor compositions containing a therapeutically effective amount of ET-743 and an amount of a PARP-1 inhibitor effective to increase the tumor cytotoxicity of the ET-743 are also presented.
Abstract: A method of treating the human body for cancer comprises administering an effective therapeutic amount of a Pegylated Liposomal form of the anthracycline Doxorubicin (“PLD”), in combination with an effective therapeutic amount of ET-743
Type:
Application
Filed:
October 26, 2005
Publication date:
May 7, 2009
Applicant:
Pharma Mar, S.A. Sociedad Unipersonal
Inventors:
Erard Gilles, Lars-Axel Sternas, Ovid Trifan, Helgi van de Velde, April Teitelbaum
Abstract: We have found anti-inflammatory activity in the ecteinascidin compounds. Such compounds have been widely described, and may have the following general formula (I), wherein: R5 is OH, alkoxy or alkanoyloxy; R6 is hydrogen, alkyl, alkenyl, alkynyl or aryl; R12 is hydrogen, alkyl, alkenyl, alkynyl or aryl; R16 is hydrogen, alkyl, alkenyl, alkynyl or aryl; R17 is OH, alkoxy or alkanoyloxy; R18 is OH, alkoxy or alkanoyloxy; R21 is H, OH, CN or another nucleophilic group; and Ra is hydrogen and Rb is optionally substituted amino, or Ra with Rb form a carbonyl function ?O, or Ra, Rb and the carbon to which they are attached form a tetrahydroisoquinoline group.
Abstract: We have found anti-inflammatory activity in the ecteinascidin compounds. Such compounds have been widely described, and may have the following general formula (I): wherein: R5 is OH, alkoxy or alkanoyloxy; R6 is hydrogen, alkyl, alkenyl, alkynyl or aryl; R12 is hydrogen, alkyl, alkenyl, alkynyl or aryl; R16 is hydrogen, alkyl, alkenyl, alkynyl or aryl; R17 is OH, alkoxy or alkanoyloxy; R18 is OH, alkoxy or alkanoyloxy; R21 is H, OH, CN or another nucleophilic group; and Ra is hydrogen and Rb is optionally substituted amino, or Ra with Rb form a carbonyl function ?O, or Ra, Rb and the carbon to which they are attached form a tetrahydroisoquinoline group.
Type:
Application
Filed:
September 28, 2005
Publication date:
March 27, 2008
Applicant:
Pharma Mar S.A. Sociedad Unipersonal
Inventors:
Paola Allavena, Maurizio D'Incalci, Glynn Thomas Faircloth